Acurx Pharmaceuticals, Inc. (ACXP)
NASDAQ: ACXP · Real-Time Price · USD
4.270
-0.010 (-0.23%)
At close: Mar 25, 2026, 4:00 PM EDT
4.270
0.00 (0.00%)
Pre-market: Mar 26, 2026, 5:10 AM EDT

Acurx Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
6.268.728.537.3410.78
Research & Development
1.835.46.044.752.03
Total Operating Expenses
8.0914.1214.5812.0912.81
Operating Income
-8.09-14.12-14.58-12.09-12.81
Interest Income
0.130.02---
Other Non-Operating Income (Expense)
----0.07
Total Non-Operating Income (Expense)
0.130.02--0.07
Pretax Income
-7.97-14.1-14.58-12.09-12.75
Net Income
-7.97-14.1-14.58-12.09-12.75
Net Income to Common
-7.97-14.1-14.58-12.09-12.75
Shares Outstanding (Basic)
11110
Shares Outstanding (Diluted)
11110
Shares Change (YoY)
85.46%27.56%17.15%26.72%37.88%
EPS (Basic)
-5.32-17.45-23.00-22.40-29.80
EPS (Diluted)
-5.32-17.45-23.00-22.40-29.80
Free Cash Flow
-6.79-10.38-9.8-7.54-5.01
Free Cash Flow Per Share
-4.53-12.85-15.47-13.95-11.75
EBITDA
-8.09-14.12-14.58-12.09-12.81
EBIT
-8.09-14.12-14.58-12.09-12.81
Updated Mar 12, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q